Keryx Biopharmaceuticals  

(Public, NASDAQ:KERX)   Watch this stock  
Find more results for KERX
10.30
+0.01 (0.10%)
Real-time:   10:44AM EDT
NASDAQ real-time data - Disclaimer
Currency in USD
Range 10.15 - 10.47
52 week 8.84 - 18.48
Open 10.33
Vol / Avg. 196,727.00/2.04M
Mkt cap 1.07B
P/E     -
Div/yield     -
EPS -1.34
Shares 103.60M
Beta 3.15
Inst. own 91%
Aug 5, 2015
Q2 2015 Keryx Biopharmaceuticals Inc Earnings Release (Estimated) - 9:30AM EDT - Add to calendar
Jun 16, 2015
Keryx Biopharmaceuticals Inc Annual Shareholders Meeting - 10:00AM EDT - Add to calendar
May 13, 2015
Keryx Biopharmaceuticals, Inc. at Bank of America Merrill Lynch 2015 Health Care Conference
May 4, 2015
Q1 2015 Keryx Biopharmaceuticals Inc Earnings Release
May 4, 2015
Q1 2015 Keryx Biopharmaceuticals Inc Earnings Call - Webcast
Mar 9, 2015
Keryx Biopharmaceuticals Inc at ROTH Conference - Webcast
Mar 2, 2015
Keryx Biopharmaceuticals Inc at Cowen Health Care Conference - Webcast
Feb 27, 2015
Q4 2014 Keryx Biopharmaceuticals Inc Earnings Release
Feb 27, 2015
Q4 2014 Keryx Biopharmaceuticals Inc Earnings Call - Webcast
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '15) 2014
Net profit margin -2360.77% -1030.19%
Operating margin -2368.00% -1027.52%
EBITD margin - -1024.69%
Return on average assets -71.93% -135.67%
Return on average equity -91.94% -187.61%
Employees 155 -
CDP Score - -

Address

750 Lexington Ave
NEW YORK, NY 10022-1200
United States - Map
+1-212-5315965 (Phone)
+1-212-5315961 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Keryx Biopharmaceuticals, Inc. is a biopharmaceutical company focused on the acquisition, development and commercialization of pharmaceutical products for the treatment of renal disease. The Company is developing Zerenex (ferric citrate coordination complex), an oral, ferric iron-based compound. The Company has completed a United States-based Phase 3 clinical program for Zerenex for the treatment of hyperphosphatemia (elevated phosphate levels) in patients with chronic kidney disease, or CKD, on dialysis, conducted pursuant to a Special Protocol Assessment, or SPA, agreement with the United States Food and Drug Administration, or FDA. The Company has also completed a United States-based Phase 2 study of Zerenex for the management of elevated serum phosphorus levels and iron deficiency anemia in subjects with Stage 3 to 5 NDD-CKD.

Officers and directors

Michael P. Tarnok Independent Chairman of the Board
Age: 60
Bio & Compensation  - Reuters
James F. Oliviero III Chief Financial Officer, Treasurer, Corporate Secretary
Age: 39
Bio & Compensation  - Reuters
Gregory P. Madison Chief Executive Officer, Director
Age: 47
Bio & Compensation  - Reuters
Brian R. Adams Vice President, General Counsel
Age: 41
Bio & Compensation  - Reuters
Abraham Ceesay Vice President of Marketing
Bio & Compensation  - Reuters
John F. Neylan Chief Medical Officer
Age: 62
Bio & Compensation  - Reuters
Lauren Fischer Director
Bio & Compensation  - Reuters
Kevin J. Cameron Independent Director
Age: 46
Bio & Compensation  - Reuters
Joseph M. Feczko M.D. Independent Director
Age: 66
Bio & Compensation  - Reuters
Wyche Fowler Jr., J.D Independent Director
Age: 74
Bio & Compensation  - Reuters